Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder
– Successful Completion of Animal Drug Interaction Studies Triggers Funding for Phase 1b Clinical Trial in Patients with CUD – SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced that it has received a funding commitment from…